There Is No Care Without Collaboration
Management of Metastatic Colorectal Cancer
Join us in Chicago for a timely and important discussion on refractory metastatic colorectal cancer (mCRC). In this 90-minute symposium, a panel of experts in refractory mCRC will guide learners through a number of patient cases to build a strong foundation of information for using new and emerging therapies effectively within their clinical practice and enhance their patient interactivity skills when providing patient-centric care.
Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer® the ASCO Foundation.
MODERATOR
Marwan Fakih, MD
Professor, Medical Oncology and Therapeutics Research
Judy and Bernard Briskin Distinguished Director in Clinical Research
Associate Director for Clinical Sciences
Medical Director, Briskin Center for Clinical Research
Division Head, GI Medical Oncology
City of Hope Comprehensive Cancer Center
Duarte, California
Arvind N. Dasari, MD, MS
Associate Professor
Department of GI Medical Oncology
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Cathy Eng, MD, FACP
David H. Johnson Chair in Surgical and Medical Oncology
Professor of Medicine, Hematology, and Oncology
Co-Director, GI Oncology
Co-leader, Gastrointestinal Cancer Research Program
Director of Strategic Relations, VICC
Executive Director, VICC Young Adult Cancers Program
Vanderbilt Health
Nashville, Tennessee
Phuong K Ly- Gallagher
Research Advocate Training and Support Program Manager,
Fight Colorectal Cancer
Pasadena, California
6:15 pm
6:45 pm
6:50 pm
7:15 pm
7:40 pm
8:05 pm
8:15 pm
720 S Michigan Ave, Chicago, Illinois, 60605
Room: Continental B
The goal of this activity is for learners to be better able to understand the biological and clinical rationale for therapies used to treat metastatic colorectal cancer (mCRC), to enhance their ability to stay up to date with new and emerging data, and to increase their awareness of treatment-related adverse events and elevate their confidence in implementing these therapies into practice.
This activity is intended for a global audience of oncologists, gastroenterologists, pathologists, oncology nurses, and other healthcare specialists who manage patients with mCRC.
Upon completion of this activity, participants will:
Have increased knowledge regarding the
Have greater competence related to
Demonstrate greater confidence in their ability to
In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs.
Medscape designates this continuing education activity for 1.50 contact hour(s) (0.150 CEUs) (Universal Activity Number: JA0007105-0000-24-137-L01-P).